Physician profile
Anu Sampat
NPI 1437116076
$13,046.52
in general payments reported to CMS, 2019-2025
35 companies · $2,622 in 2025
The $2,622 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $805 · 2021: $1,682 · 2022: $2,288 · 2023: $2,397 · 2024: $2,433 · 2025: $2,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,370 · Education: $81.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,370.07 |
| Education | $81.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,718.13 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $1,413.02 | 2019-2025 | Linzess, Viberzi, Creon |
| Janssen Biotech, INC. | $1,225.57 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $1,189.79 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $859.84 | 2021-2025 | |
| Celgene Corporation | $685.67 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $659.67 | 2021-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $529.04 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $485.02 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $458.19 | 2019-2024 | Linzess |
| Braintree Laboratories, INC. | $412.65 | 2019-2025 | Suflave, Sutab |
| Gilead Sciences, INC. | $358.69 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $316.30 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $295.72 | 2024-2025 | Omvoh, Zepbound |
| Redhill Biopharma INC. | $220.91 | 2020-2024 | Talicia |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $174.48 | 2020-2023 | |
| Intercept Pharmaceuticals, INC. | $171.90 | 2021-2023 | Ocaliva |
| Ferring Pharmaceuticals INC. | $161.76 | 2019-2024 | Rebyota, Cimzia |
| Merck Sharp & Dohme LLC | $143.10 | 2023-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $82.81 | 2022-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $66.57 | 2024-2025 | Iqirvo |
| Concordia Pharmaceuticals INC. | $49.28 | 2019 | |
| Genzyme Corporation | $49.23 | 2023-2024 | |
| Glaxosmithkline, LLC. | $48.30 | 2025 | Nucala |
| Allergan, INC. | $48.19 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $46.82 | 2024-2025 | Vowst |
| Janssen Pharmaceuticals, INC | $36.52 | 2020 | |
| Vivus LLC | $22.87 | 2024 | Qsymia |
| W. L. Gore & Associates, INC. | $21.57 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $21.17 | 2025 | Kristalose |
| Novo Nordisk INC | $19.69 | 2025 | Wegovy |
| Evoke Pharma, INC. | $17.16 | 2022 | |
| Alfasigma USA, INC. | $13.24 | 2020 | |
| Organon LLC | $13.07 | 2023 | Hadlima, Renflexis |
| Romark Laboratories, Lc | $10.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anu Sampat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.